DK1054955T3 - Sammensætninger omfattende vira og fremgangsmåde til at opkoncentrere viruspræparater - Google Patents

Sammensætninger omfattende vira og fremgangsmåde til at opkoncentrere viruspræparater

Info

Publication number: DK1054955T3
Authority: DK; Denmark
Prior art keywords: viruses; compositions; methods; virus preparations; concentrating virus
Prior art date: 1998-02-17

Application number

DK99906690T

Other languages

Danish (da)

English (en)

Inventor

Andreas Frei

Henry K H Kwan

Varda E Sandweiss

Gary J Vellekamp

Pui-Ho Yuen

Laureano L Bondoc Jr

John Chu-Tay Tang

Peter Ihnat

Frederick William Porter Iv

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-17

Filing date

1999-02-12

Publication date

2007-01-15

1999-02-12 Application filed by Schering Corp filed Critical Schering Corp

2007-01-15 Application granted granted Critical

2007-01-15 Publication of DK1054955T3 publication Critical patent/DK1054955T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Immunology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK99906690T 1998-02-17 1999-02-12 Sammensætninger omfattende vira og fremgangsmåde til at opkoncentrere viruspræparater DK1054955T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2446298A	1998-02-17	1998-02-17
US7964398A	1998-05-15	1998-05-15

Publications (1)

Publication Number	Publication Date
DK1054955T3 true DK1054955T3 (da)	2007-01-15

Family

ID=26698472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99906690T DK1054955T3 (da)	1998-02-17	1999-02-12	Sammensætninger omfattende vira og fremgangsmåde til at opkoncentrere viruspræparater

Country Status (25)

Country	Link
EP (4)	EP1741777B1 (pt)
JP (3)	JP4358434B2 (pt)
KR (5)	KR100918187B1 (pt)
CN (2)	CN101164623B (pt)
AR (3)	AR020054A1 (pt)
AT (3)	ATE478945T1 (pt)
AU (1)	AU757976B2 (pt)
BR (1)	BR9908015A (pt)
CA (2)	CA2320419C (pt)
CO (1)	CO4820440A1 (pt)
DE (3)	DE69942708D1 (pt)
DK (1)	DK1054955T3 (pt)
ES (2)	ES2290613T3 (pt)
HK (3)	HK1073481A1 (pt)
HU (1)	HU226015B1 (pt)
ID (1)	ID28298A (pt)
IL (2)	IL137510A0 (pt)
MY (1)	MY141641A (pt)
NO (1)	NO20004104L (pt)
PE (1)	PE20000265A1 (pt)
PL (1)	PL197747B1 (pt)
PT (1)	PT1054955E (pt)
SK (1)	SK11842000A3 (pt)
TW (1)	TWI232107B (pt)
WO (1)	WO1999041416A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2272820C (en)	1996-11-20	2012-09-11	Introgen Therapeutics, Inc.	An improved method for the production and purification of adenoviral vectors
US7732129B1 (en)	1998-12-01	2010-06-08	Crucell Holland B.V.	Method for the production and purification of adenoviral vectors
WO2000029024A1 (en) *	1998-11-16	2000-05-25	Introgen Therapeutics, Inc.	Formulation of adenovirus for gene therapy
US6689600B1 (en)	1998-11-16	2004-02-10	Introgen Therapeutics, Inc.	Formulation of adenovirus for gene therapy
CA2799545A1 (en) *	2000-03-07	2001-09-13	Merck Sharp & Dohme Corp.	Adenovirus formulations
US7456009B2 (en)	2000-03-07	2008-11-25	Merck & Co., Inc.	Adenovirus formulations
US20020064860A1 (en)	2000-11-29	2002-05-30	Schering Corporation	Method for purifying adenoviruses
JP2002241311A (ja) *	2000-12-12	2002-08-28	Japan Tobacco Inc	界面活性剤を含む医薬組成物
WO2003049763A1 (en)	2001-12-12	2003-06-19	Fh Faulding & Co Limited	Composition for the preservation of viruses
US20030153065A1 (en) *	2002-01-14	2003-08-14	Genvec, Inc.	Composition and method for maintaining non-enveloped viral vectors
PL371261A1 (en) *	2002-01-18	2005-06-13	Schering Aktiengesellschaft	Stabilized formulations of adenovirus
WO2005080556A2 (en)	2004-02-23	2005-09-01	Crucell Holland B.V.	Virus purification methods
KR20070104339A (ko)	2004-11-03	2007-10-25	인트로겐 테라페티스, 인코퍼레이티드	아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
MX2007007145A (es)	2004-12-13	2007-08-20	Canji Inc	Lineas de celulas para produccion de adenovirus con replicacion defectuosa.
US8574595B2 (en)	2005-04-11	2013-11-05	Crucell Holland B.V.	Virus purification using ultrafiltration
CN1961961B (zh) *	2005-11-11	2010-05-26	深圳市源兴生物医药科技有限公司	一种药物制剂及其制备方法
DE602006019916D1 (de)	2005-12-12	2011-03-10	Canji Inc	Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
EP2007883B1 (en) *	2006-04-20	2011-12-28	Wyeth LLC	Purification processes for isolating purified vesicular stomatitis virus from cell culture
DK2350268T3 (en)	2008-11-03	2015-03-23	Crucell Holland Bv	PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
ES2903127T3 (es)	2009-05-02	2022-03-31	Genzyme Corp	Terapia génica para trastornos neurodegenerativos
EP2536829B1 (en)	2010-02-15	2016-04-06	Crucell Holland B.V.	Method for the production of Ad26 adenoviral vectors
CN103118702A (zh)	2010-09-20	2013-05-22	克鲁塞尔荷兰公司	活动性结核病的治疗性接种
AU2011310838B2 (en)	2010-09-27	2015-11-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
MX349294B (es)	2010-12-02	2017-07-21	Oncolytics Biotech Inc	Formulaciones virales liofilizadas.
AU2011336413B2 (en)	2010-12-02	2015-01-22	Oncolytics Biotech Inc.	Liquid viral formulations
SG194449A1 (en) *	2011-04-29	2013-12-30	Oncolytics Biotech Inc	Methods of purifying viruses using gel permeation chromatography
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl)	2012-03-12	2016-10-31		Partie rekombinowanych adenowirusów o zmienionych końcach
WO2013139911A1 (en)	2012-03-22	2013-09-26	Crucell Holland B.V.	Vaccine against rsv
US9119813B2 (en)	2012-03-22	2015-09-01	Crucell Holland B.V.	Vaccine against RSV
CA2910067C (en)	2013-04-25	2023-10-17	Crucell Holland B.V.	Stabilized soluble pre-fusion rsv f polypeptides
EA034653B1 (ru)	2013-06-17	2020-03-03	Янссен Вэксинс Энд Превеншн Б.В.	Стабилизированные растворимые f-полипептиды rsv перед слиянием
KR20170004966A (ko) *	2014-05-28	2017-01-11	에이전시 포 사이언스, 테크놀로지 앤드 리서치	바이러스 감소 방법
EP3283634B1 (en)	2015-04-14	2019-05-22	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289496B2 (en)	2015-07-07	2021-02-04	Janssen Vaccines & Prevention B.V.	Stabilized soluble pre-fusion RSV F polypeptides
EP3319633B1 (en)	2015-07-07	2020-11-11	Janssen Vaccines & Prevention B.V.	Vaccine against rsv
DK3439672T3 (da)	2016-04-05	2021-02-15	Janssen Vaccines & Prevention Bv	Stabiliserede opløselige præfusions-rsv-f-proteiner
SG11201807912SA (en)	2016-04-05	2018-10-30	Janssen Vaccines & Prevention Bv	Vaccine against rsv
EP3464331B1 (en)	2016-05-30	2020-10-28	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
CA3027807A1 (en)	2016-06-20	2017-12-28	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
WO2018011196A1 (en)	2016-07-14	2018-01-18	Janssen Vaccines & Prevention B.V.	Hpv vaccines
WO2018210871A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
US11229692B2 (en)	2017-05-17	2022-01-25	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against RSV infection
WO2019021305A1 (en) *	2017-07-24	2019-01-31	Ella Foundation	VACCINE AGAINST FOOT AND MOUTH DISEASE
US11229695B2 (en)	2017-09-15	2022-01-25	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against RSV
JP7539420B2 (ja)	2019-06-28	2024-08-23	武田薬品工業株式会社	アデノ随伴ウイルスの精製方法
BR112022014808A2 (pt)	2020-01-31	2022-09-20	Beth Israel Deaconess Medical Ct Inc	Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
MX2023009738A (es)	2021-02-19	2023-08-30	Janssen Vaccines & Prevention Bv	Antigenos de rsv fb prefusion estabilizados.
WO2023020939A1 (en)	2021-08-17	2023-02-23	Janssen Pharmaceuticals, Inc.	Sars-cov-2 vaccines
WO2023020556A1 (zh) *	2021-08-17	2023-02-23	上海行深生物科技有限公司	病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en)	2021-12-14	2023-06-22	Janssen Pharmaceuticals, Inc.	Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE299213C (pt) *
US4147772A (en) *	1976-02-03	1979-04-03	Merck & Co., Inc.	Vaccine stabilizer
GB1575155A (en) *	1978-04-11	1980-09-17	Merck & Co Inc	Vaccine stabilizer
BE866330A (fr) *	1978-04-25	1978-10-25	Merck & Co Inc	Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en)	1987-08-31	1996-07-02	The Regents Of The University Of California	Genetic mechanisms of tumor suppression
DD299213A7 (de) *	1988-05-04	1992-04-09	Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De	Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) *	1988-05-06	1991-11-14	Saechsisches Serumwerk Gmbh Dresden,	Immobilisiertes immunologisch aktives reagens
BR9407956A (pt)	1993-10-25	1996-11-26	Canji Inc	Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
KR100368686B1 (ko) *	1994-12-29	2003-12-01	주식회사 엘지생명과학	수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) *	1995-12-22	1998-04-03	Pasteur Merieux Serums Vacc	Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en)	1996-01-08	1998-08-04	Canji, Inc.	Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

1999
- 1999-02-12 AT AT06019642T patent/ATE478945T1/de not_active IP Right Cessation
- 1999-02-12 CN CN2007101670867A patent/CN101164623B/zh not_active Expired - Fee Related
- 1999-02-12 ES ES04030395T patent/ES2290613T3/es not_active Expired - Lifetime
- 1999-02-12 AU AU26538/99A patent/AU757976B2/en not_active Ceased
- 1999-02-12 AT AT99906690T patent/ATE341614T1/de not_active IP Right Cessation
- 1999-02-12 DE DE69942708T patent/DE69942708D1/de not_active Expired - Lifetime
- 1999-02-12 DE DE69936948T patent/DE69936948T2/de not_active Expired - Lifetime
- 1999-02-12 KR KR1020087008929A patent/KR100918187B1/ko not_active IP Right Cessation
- 1999-02-12 EP EP06019642A patent/EP1741777B1/en not_active Expired - Lifetime
- 1999-02-12 WO PCT/US1999/001873 patent/WO1999041416A2/en active IP Right Grant
- 1999-02-12 IL IL13751099A patent/IL137510A0/xx unknown
- 1999-02-12 EP EP04030395A patent/EP1526174B1/en not_active Expired - Lifetime
- 1999-02-12 HU HU0100670A patent/HU226015B1/hu not_active IP Right Cessation
- 1999-02-12 DK DK99906690T patent/DK1054955T3/da active
- 1999-02-12 SK SK1184-2000A patent/SK11842000A3/sk unknown
- 1999-02-12 EP EP04030394A patent/EP1526173B1/en not_active Expired - Lifetime
- 1999-02-12 JP JP2000531596A patent/JP4358434B2/ja not_active Expired - Fee Related
- 1999-02-12 ES ES99906690T patent/ES2272053T3/es not_active Expired - Lifetime
- 1999-02-12 ID IDW20001574A patent/ID28298A/id unknown
- 1999-02-12 KR KR1020097004676A patent/KR100991683B1/ko not_active IP Right Cessation
- 1999-02-12 PL PL342847A patent/PL197747B1/pl not_active IP Right Cessation
- 1999-02-12 PT PT99906690T patent/PT1054955E/pt unknown
- 1999-02-12 KR KR1020007008878A patent/KR100862169B1/ko not_active IP Right Cessation
- 1999-02-12 DE DE69933433T patent/DE69933433T2/de not_active Expired - Lifetime
- 1999-02-12 KR KR1020097022935A patent/KR101018992B1/ko not_active IP Right Cessation
- 1999-02-12 AT AT04030395T patent/ATE371020T1/de not_active IP Right Cessation
- 1999-02-12 TW TW088102219A patent/TWI232107B/zh not_active IP Right Cessation
- 1999-02-12 CN CNB998050989A patent/CN100374551C/zh not_active Expired - Fee Related
- 1999-02-12 CA CA2320419A patent/CA2320419C/en not_active Expired - Fee Related
- 1999-02-12 BR BR9908015-0A patent/BR9908015A/pt not_active Application Discontinuation
- 1999-02-12 KR KR1020087008928A patent/KR100912362B1/ko not_active IP Right Cessation
- 1999-02-12 EP EP99906690A patent/EP1054955B1/en not_active Expired - Lifetime
- 1999-02-12 CA CA2723040A patent/CA2723040A1/en not_active Abandoned
- 1999-02-15 MY MYPI99000542A patent/MY141641A/en unknown
- 1999-02-16 CO CO99009282A patent/CO4820440A1/es unknown
- 1999-02-16 PE PE1999000137A patent/PE20000265A1/es not_active Application Discontinuation
- 1999-02-23 AR ARP990100656A patent/AR020054A1/es active IP Right Grant
2000
- 2000-07-25 IL IL137510A patent/IL137510A/en not_active IP Right Cessation
- 2000-08-16 NO NO20004104A patent/NO20004104L/no not_active Application Discontinuation
- 2000-12-01 HK HK05106734A patent/HK1073481A1/xx not_active IP Right Cessation
- 2000-12-01 HK HK00107727A patent/HK1028416A1/xx not_active IP Right Cessation
2006
- 2006-02-07 JP JP2006030336A patent/JP2006166925A/ja not_active Withdrawn
2007
- 2007-05-10 HK HK07104995.0A patent/HK1097413A1/xx not_active IP Right Cessation
- 2007-10-16 AR ARP070104577A patent/AR063315A2/es unknown
- 2007-10-16 AR ARP070104576A patent/AR063314A2/es unknown
2010
- 2010-07-08 JP JP2010156257A patent/JP2010213727A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20010072547A (ko)	2001-07-31
EP1526173A3 (en)	2005-08-10
NO20004104L (no)	2000-10-17
CN1297478A (zh)	2001-05-30
TWI232107B (en)	2005-05-11
EP1526174A3 (en)	2005-08-31
EP1054955B1 (en)	2006-10-04
JP2002503484A (ja)	2002-02-05
ES2290613T3 (es)	2008-02-16
PE20000265A1 (es)	2000-04-25
EP1526173A2 (en)	2005-04-27
EP1054955A2 (en)	2000-11-29
EP1741777A1 (en)	2007-01-10
ID28298A (id)	2001-05-10
CO4820440A1 (es)	1999-07-28
AR063315A2 (es)	2009-01-21
CN101164623B (zh)	2012-11-14
KR20090127947A (ko)	2009-12-14
CA2320419C (en)	2011-02-08
CA2723040A1 (en)	1999-08-19
KR100912362B1 (ko)	2009-08-19
EP1526173B1 (en)	2012-11-21
PL342847A1 (en)	2001-07-16
AR063314A2 (es)	2009-01-21
ATE341614T1 (de)	2006-10-15
WO1999041416A3 (en)	1999-11-18
KR100991683B1 (ko)	2010-11-04
AU757976B2 (en)	2003-03-13
KR20080065615A (ko)	2008-07-14
MY141641A (en)	2010-05-31
DE69933433T2 (de)	2007-08-23
CN100374551C (zh)	2008-03-12
AU2653899A (en)	1999-08-30
HUP0100670A3 (en)	2003-10-28
AR020054A1 (es)	2002-04-10
IL137510A (en)	2012-10-31
EP1526174B1 (en)	2007-08-22
DE69936948D1 (de)	2007-10-04
DE69933433D1 (de)	2006-11-16
ATE478945T1 (de)	2010-09-15
JP4358434B2 (ja)	2009-11-04
PT1054955E (pt)	2007-01-31
CA2320419A1 (en)	1999-08-19
EP1526174A2 (en)	2005-04-27
WO1999041416A2 (en)	1999-08-19
HU226015B1 (en)	2008-02-28
CN101164623A (zh)	2008-04-23
HK1028416A1 (en)	2001-02-16
KR101018992B1 (ko)	2011-03-07
DE69942708D1 (de)	2010-10-07
JP2006166925A (ja)	2006-06-29
BR9908015A (pt)	2001-04-24
KR20090038927A (ko)	2009-04-21
KR20080065614A (ko)	2008-07-14
SK11842000A3 (sk)	2001-05-10
ES2272053T3 (es)	2007-04-16
KR100918187B1 (ko)	2009-09-22
HUP0100670A2 (hu)	2001-06-28
NO20004104D0 (no)	2000-08-16
JP2010213727A (ja)	2010-09-30
HK1097413A1 (en)	2007-06-22
HK1073481A1 (en)	2005-10-07
PL197747B1 (pl)	2008-04-30
DE69936948T2 (de)	2008-05-15
EP1741777B1 (en)	2010-08-25
IL137510A0 (en)	2001-07-24
KR100862169B1 (ko)	2008-10-09
ATE371020T1 (de)	2007-09-15

Publication	Publication Date	Title
DK1054955T3 (da)	2007-01-15	Sammensætninger omfattende vira og fremgangsmåde til at opkoncentrere viruspræparater
ATE275631T1 (de)	2004-09-15	Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff
NO20025627L (no)	2003-01-06	Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
IS5953A (is)	2001-05-25	Lyfjablöndur úr örgerðum eplerenonum
ID21649A (id)	1999-07-08	Inhibitor serum protease, terutama virus hepatitis c ns3 protease
NO20001409D0 (no)	2000-03-17	Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
DK1109453T3 (da)	2012-11-19	Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme
ID27457A (id)	2001-04-12	Komposisi untuk pengobatan hiv dan infeksi virus lainnya
NO20011162D0 (no)	2001-03-07	FremgangsmÕter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
ATE245026T1 (de)	2003-08-15	2-phenyl-1-(-(2-aminoethoxy)-benzyl -indol und estrogen als kombinationpräparate
NO971495L (no)	1997-05-26	Svekkede virus og fremgangsmåte til deres fremstilling
EP1052988A4 (en)	2003-05-28	USEFUL METHODS AND COMPOSITIONS FOR INACTIVATING VIRUSES
DE69925820D1 (de)	2005-07-21	Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
IS5777A (is)	2000-12-19	Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
NO983472D0 (no)	1998-07-28	Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
NO20010464L (no)	2001-03-23	FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
NO20022969D0 (no)	2002-06-20	Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav
DE69926012D1 (de)	2005-08-04	Arzneizubereitungen
NO20024325D0 (no)	2002-09-10	Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
EP1539938A4 (en)	2007-11-28	CHIMERIC GB-VIRUS B (GBV-B)
ZA991235B (en)	2000-09-16	Compositions comprising viruses and methods for concentrating virus preparations.
NO20041815L (no)	2004-06-11	Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon
DE69824881D1 (de)	2004-08-05	Kompakte replikons des epstein-barr-virus.
JP2002519670A5 (ja)	2006-08-31	Ｃ型レトロウイルス感染の検出のための方法および組成物
DK1064393T3 (da)	2005-04-25	Sammensætninger og fremgangsmåder til hjælper-fri produktion af rekombinante adenoassocierede virusser